Big Idea:

Vivodyne, a biotech research startup, has announced $38 million in funding led by Khosla Ventures. Vivodyne leverages AI-scale testing on lab-grown human organs for preclinical testing for every stage of drug development.

Why It Matters:

Vivodyne enables their biopharma partners to see human data even before clinical trials and reduces the need for animal testing. Their platform can mimic drug interactions with human cells offering more precise results, enhance drug success rates and accelerate the discovery of more effective treatments.

Key Details:

• Vivodyne's technology generates early human data, aiding in the identification of promising drugs while potentially cutting costs and lowering drug prices.
• The company has developed 22 types of bioengineered human organ tissues, integrated with AI, to mimic human responses to drugs.
• The AI platform can handle over 10,000 tissue samples simultaneously, using robotic automation for large-scale, human-like data generation.
• The technology is not limited to drug discovery; it also extends to troubleshooting issues in human trials.

“We’re thrilled to have Khosla Ventures lead this funding round, which accelerates the development of our AI platform that enables the generation of predictive human data before therapeutics enter clinical trials,” said Andrei Georgescu, CEO and Co-Founder of Vivodyne.

What's Next:

Vivodyne plans to expand its platform and potentially collaborate with top biopharma companies. This expansion aims to advance AI-driven drug discovery using its extensive human data sets.

‍